Teva Pharmaceutical Industries Limited (TEVA) Q2 2024 Earnings Call TranscriptSeeking Alpha • 07/31/24
Medincell's partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progressBusiness Wire • 07/31/24
Teva Pharmaceutical Industries (TEVA) Reports Q2 Earnings: What Key Metrics Have to SayZacks Investment Research • 07/31/24
Is Teva Pharmaceutical Industries (TEVA) Stock Undervalued Right Now?Zacks Investment Research • 07/31/24
Teva Pharma Flirts With Breakout As Generic Drugs Drive Beat-And-RaiseInvestors Business Daily • 07/31/24
Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug salesReuters • 07/31/24
Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 07/29/24
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel DiseaseBusiness Wire • 07/25/24
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic MigraineBusiness Wire • 07/18/24
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024Business Wire • 07/02/24
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment PausesBusiness Wire • 06/28/24
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020Business Wire • 06/25/24
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United StatesBusiness Wire • 06/24/24
Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/11/24